TNGX Tango Pharma Company Assets

TNGX (Tango Pharma) - company brandmark

Tango Therapeutics (TNGX) supports the development of targeted cancer therapies via synthetic lethality and the success of the TNG908 inhibitor through alliances with pharma behemoths to diversify risks. The market trend of total asset value, which currently stands at 655.99, serves as a capital indicator. Tango Therapeutics (TNGX) generates revenue by creating innovative therapy methods, leveraging genetic analysis and strategic biopharmaceutical collaborations.

TNGX - Tango Therapeutics, Inc. Company Total Assets over the range 07/04/2022 - 10/30/2026

Analytical breakdowns and data insights for company Tango Pharma (TNGX)

- stock quotes and analyst forecast:
Share Price tangotx.com|TNGX - Price Target Chart
- market capitalization data:
Market Value Tango Therapeutics Corp|TNGX - Total Company Value
- balance sheet equity data:
Equity per Share Tango Therapeutics|TNGX - Book Capitalization|Market Cap to Net Assets Ratio tangotx.com|TNGX - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Tango Therapeutics|TNGX - Long-Term Debt to Equity|Short-Term Debt to Equity Tango Therapeutics Corp|TNGX - Company Debts|Debts to Book Value Tango Therapeutics Corp|TNGX - Company Long-Term Debts|Short-Term Indebtedness Tango Therapeutics|Immediate Liquidity tangotx.com
- earnings and market ratios statistics:
TNGX - Net Income
Basic company analysis:TNGX tangotx.com
Signature product of Tango Therapeutics Corp

A comparative analysis of total assets allows an investor to evaluate capital efficiency relative to the WACC rate to eliminate the risk of business value destruction. The current value of 655.99, calculated inversely via ROA, reflects the volume of resources allocated to the development of the synthetic lethality platform and TNG908 clinical trials, which is clearly confirmed by the history of controlled resources for Tango Therapeutics (TNGX).

Direct competitors

Total Business Assets IBRX|Aggregate Company Assets Immunocore|Company Assets Janux Therapeutics Inc JANX|Aggregate Company Assets Arcus Bio (RCUS)|Zymeworks Biopharmaceuticals - Total Business Assets|Company Total Assets IOVA (Iovance Biotherapeutics)|IMTX - Cumulative Company Assets|XNCR - Aggregate Company Assets|Company Assets Compass Therapeutics Inc|Replimune Corp (REPL) - Aggregate Company Assets|LYEL (Lyell Pharma) - Aggregate Company Assets|Aggregate Company Assets Innate Pharma S.A.|Company Assets Pyxis PYXS|Company Total Assets CGEN|IO Biotech Inc (IOBT) - Company Balance Sheet Assets|Sutro Bio - Cumulative Company Assets|MiNK Therapeutics, Inc (INKT) - Company Assets|HOWL: Cumulative Company Assets|Aggregate Asset Value IMMX (Immix Biopharma, Inc.)|ALXO: Company Total Assets|CUE - Company Total Asset Base|Aggregate Company Assets PDS Biotech|Cumulative Company Assets Sonnet BioTherapeutics Holdings Inc. (SONN)|Aggregate Company Assets MAIA Biotechnology (MAIA)|Cumulative Company Assets liminatuspharma.com LIMN|LAVA Therapeutics - Cumulative Company Assets|Company Total Assets NextCure Inc NXTC|LPTX - Aggregate Company Assets|INTS (Intensity Therapeutics) - Total Business Assets|senseibio.com (SNSE) - Aggregate Company Assets|Company Assets therivabio.com (TOVX)|Cumulative Company Assets GRTS|KA - Company Balance Sheet Assets|Cumulative Company Assets NEXI (NexImmune Corp)|Aggregate Business Assets TSBX|Company Total Assets VCNX (Vaccinex, Inc.)|Aggregate Asset Value HARP